MeSA methylseleninic acid
Description: <b>Methylseleninic acid</b>, a widespread selenium-containing compound of organic nature.<br>
<p><b>Methylseleninic acid</b> — Methylseleninic acid is a monomethylated organoselenium small molecule and experimental selenium-based anticancer/chemopreventive agent that functions as a proximal precursor of methylselenol without requiring β-lyase activation. It is commonly abbreviated MSeA or MSA; MeSA is also used but is potentially ambiguous with methyl salicylate. MSeA is primarily an experimental compound rather than a dietary selenium form or approved drug. It is chemically and biologically related to Se-methylselenocysteine, but the two compounds are not mechanistically interchangeable. Its anticancer activity is strongly concentration-, cell-type-, and redox-context-dependent.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Redox/thiol disruption with ROS and lipid-peroxidation increase, oxidation of protein sulfhydryls, and context-dependent GSH depletion, producing oxidative damage preferentially in susceptible cancer cells.</li>
<li>Apoptosis induction through mitochondrial dysfunction, cytochrome-c/caspase activation, ER-stress signaling, CHOP induction, and in some models AIF-associated pathways.</li>
<li>Redox-mediated inhibition/modulation of signaling proteins including PKC isoenzymes, with downstream suppression of proliferative and survival signaling.</li>
<li>Suppression of oncogenic survival pathways including AKT, STAT3, β-catenin, androgen-receptor signaling, and context-dependent ERK signaling.</li>
<li>ER stress and unfolded-protein-response activation involving PERK/eIF2α, GRP78/GRP94 and CHOP, progressing from adaptive stress toward apoptosis at higher exposure.</li>
<li>Suppression of hypoxia/angiogenesis signaling including HIF-1α, VEGF, neuropilin-1 and Ang-2/Tie2-associated signaling.</li>
<li>Cell-cycle inhibition and antiproliferative activity, including G1 or G2/M effects depending on tumor model.</li>
<li>Chemosensitization and radiosensitization, including enhanced responses to paclitaxel, etoposide, docetaxel and ionizing radiation in preclinical models.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral MSeA is systemically absorbed in rodents and increases selenium concentrations in plasma and multiple tissues. It is metabolically useful because it provides a relatively direct route to monomethylated selenium chemistry and methylselenol without the β-lyase requirement of Se-methylselenocysteine. Human MSeA pharmacokinetics, tolerated systemic exposure, and therapeutic plasma concentrations have not been adequately established. Selenium has a comparatively narrow safety margin at pharmacologic exposure, so rodent anticancer doses cannot be directly translated into human dosing.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most direct anticancer experiments use approximately low-micromolar MSeA, commonly around 1–10 µM, although sensitivity varies substantially among models and higher concentrations are sometimes used. Comparable sustained free-MSeA concentrations have not been demonstrated as safely achievable in humans. Consequently, micromolar in-vitro findings should be considered mechanistic/preclinical rather than evidence of clinically achievable drug exposure.</p>
<p><b>Clinical evidence status:</b> Preclinical. MSeA has substantial cell-culture and animal xenograft/transgenic-model evidence, including chemotherapy and radiation sensitization, but it has not established clinical anticancer efficacy in humans and is not an approved cancer therapy. Recent reviews discussing selenium clinical translation distinguish MSeA from selenium compounds that have actually entered human oncology trials.</p>
<h3>Methylseleninic Acid Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Redox stress and ROS</td>
<td>ROS ↑; oxidative damage ↑; lipid peroxidation ↑; GSH ↓ (context-dependent)</td>
<td>ROS ↔/↓ or lower susceptibility (model-dependent)</td>
<td>P/R/G</td>
<td>Pro-oxidant cytotoxicity</td>
<td>Central anticancer mechanism in many models. ROS can occur upstream of DNA-damage signaling and apoptosis. MSeA can also act antioxidatively in some non-cancer or hormone-dependent contexts, so ROS direction is not universal.</td>
</tr>
<tr>
<td>2</td>
<td>Apoptosis and caspase signaling</td>
<td>Apoptosis ↑; caspase-3/7/9 ↑; PARP cleavage ↑</td>
<td>Apoptosis ↔/lower (model-dependent)</td>
<td>R/G</td>
<td>Programmed cell death</td>
<td>Strongly reproduced across prostate, breast, colon, glioma and other cancer systems. Execution pathway varies by cell type.</td>
</tr>
<tr>
<td>3</td>
<td>Protein thiol oxidation and PKC</td>
<td>PKC activity ↓</td>
<td>↔/↓ (context-dependent)</td>
<td>P/R</td>
<td>Redox inhibition of proliferative signaling</td>
<td>MSeA oxidizes susceptible vicinal cysteine thiols in PKC catalytic domains. Ca²⁺-dependent PKC isoenzymes are particularly susceptible, but this does not establish Ca²⁺ signaling itself as a primary MSeA mechanism.</td>
</tr>
<tr>
<td>4</td>
<td>Endoplasmic reticulum stress</td>
<td>PERK ↑; eIF2α phosphorylation ↑; GRP78 ↑; CHOP ↑; ER-stress apoptosis ↑</td>
<td>Uncertain</td>
<td>R/G</td>
<td>Proteotoxic stress and apoptosis</td>
<td>Lower exposure activates adaptive ER-stress responses; greater stress shifts signaling toward CHOP/caspase-associated death.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial dysfunction</td>
<td>Mitochondrial depolarization ↑; cytochrome-c release ↑; permeability transition ↑ (model-dependent)</td>
<td>Lower effect reported in selected models</td>
<td>R/G</td>
<td>Intrinsic apoptotic amplification</td>
<td>Mitochondrial involvement is closely linked to cellular redox state and AKT survival signaling. AIF-associated death has also been reported in selenium-compound models.</td>
</tr>
<tr>
<td>6</td>
<td>AKT survival signaling</td>
<td>AKT phosphorylation ↓ or ↑ (context-dependent)</td>
<td>↔ (model-dependent)</td>
<td>R/G</td>
<td>Reduced survival signaling</td>
<td>AKT commonly determines MSeA sensitivity, but direction is not uniform. Hypoxic prostate models can show AKT activation despite continued growth inhibition, so AKT↓ should not be treated as universal.</td>
</tr>
<tr>
<td>7</td>
<td>Androgen receptor signaling</td>
<td>AR ↓; PSA ↓</td>
<td>Not established</td>
<td>G</td>
<td>Suppression of prostate-cancer growth signaling</td>
<td>Repeatedly demonstrated across several AR-positive prostate cancer models and appears mechanistically distinct from selenite-mediated AR suppression.</td>
</tr>
<tr>
<td>8</td>
<td>β-Catenin signaling</td>
<td>Total β-catenin ↓; nuclear β-catenin ↓</td>
<td>Not established</td>
<td>G</td>
<td>Reduced proliferation and drug resistance</td>
<td>Suppression is dose- and time-dependent and can enhance cytotoxicity of multiple chemotherapeutic drugs.</td>
</tr>
<tr>
<td>9</td>
<td>HIF-1α and hypoxia signaling</td>
<td>HIF-1α ↓; REDD1 ↑</td>
<td>Not established</td>
<td>G</td>
<td>Growth inhibition under hypoxia</td>
<td>Relevant particularly in invasive prostate cancer. REDD1 induction can occur despite AKT activation and altered mTOR signaling.</td>
</tr>
<tr>
<td>10</td>
<td>Angiogenesis signaling</td>
<td>VEGF ↓; Ang-2 ↓; neuropilin-1 ↓; microvascular density ↓</td>
<td>Vascular normalization ↑ (model-dependent)</td>
<td>G</td>
<td>Antiangiogenic activity</td>
<td>Supported by breast- and prostate-tumor animal models as well as tumor-cell studies.</td>
</tr>
<tr>
<td>11</td>
<td>STAT3 and inflammatory survival signaling</td>
<td>STAT3 ↓; NF-κB ↓ (model-dependent)</td>
<td>Uncertain</td>
<td>G</td>
<td>Reduced survival and inflammatory signaling</td>
<td>Mechanistically relevant but less consistently demonstrated than redox stress, apoptosis and ER stress.</td>
</tr>
<tr>
<td>12</td>
<td>Cell cycle</td>
<td>Cell-cycle progression ↓; G1 or G2/M arrest ↑ (model-dependent)</td>
<td>Lower effect in selected non-transformed cells</td>
<td>G</td>
<td>Antiproliferative effect</td>
<td>Cell-cycle phenotype depends strongly on tumor lineage, concentration and exposure duration.</td>
</tr>
<tr>
<td>13</td>
<td>Chemosensitization</td>
<td>Paclitaxel response ↑; etoposide response ↑; docetaxel response ↑</td>
<td>Limited data</td>
<td>G</td>
<td>Enhanced treatment efficacy</td>
<td>Synergistic or strongly enhanced antitumor effects have been reported in cell and xenograft models. Clinical validation is absent.</td>
</tr>
<tr>
<td>14</td>
<td>Radiosensitization</td>
<td>Radiation sensitivity ↑; lipid peroxidation ↑</td>
<td>Radiation toxicity ↔ at comparable MSeA exposure in selected fibroblast models</td>
<td>R/G</td>
<td>Selective radiation sensitization</td>
<td>Demonstrated preclinically in head-and-neck cancer cells and linked to enhanced lipid peroxidation.</td>
</tr>
<tr>
<td>15</td>
<td>Thioredoxin reductase system</td>
<td>TrxR interaction/modulation ↔/↑; high TrxR can confer resistance</td>
<td>Selenoprotein activity ↑ (model-dependent)</td>
<td>R/G</td>
<td>Redox buffering and resistance determinant</td>
<td>MSeA is a TrxR substrate rather than a simple irreversible TrxR inhibitor. TrxR can reverse MSeA-induced thiol oxidation, and increased TrxR may reduce sensitivity. Database coding as uniformly TrxR↓ would therefore be misleading.</td>
</tr>
<tr>
<td>16</td>
<td>Clinical Translation Constraint</td>
<td>Effective concentrations commonly low µM in vitro</td>
<td>Selenium toxicity limits unrestricted systemic dosing</td>
<td>G</td>
<td>Exposure and safety limitation</td>
<td>No established therapeutic human MSeA exposure, dose, PK profile or anticancer efficacy. Rodent oral efficacy cannot be directly converted to a human treatment dose.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>